Humacyte Inc (NASDAQ:HUMA)’s traded shares stood at 0.48 million during the latest session, with the company’s beta value hitting 1.39. At the last check today, the stock’s price was $3.41, to imply an increase of 1.34% or $0.04 in intraday trading. The HUMA share’s 52-week high remains $9.97, putting it -192.38% down since that peak but still an impressive 17.6% since price per share fell to its 52-week low of $2.81.
Analysts have given a consensus recommendation of Buy for Humacyte Inc (HUMA), translating to a mean rating of 1.29. Of 2 analyst(s) looking at the stock, 0 analyst(s) give HUMA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.25.
Humacyte Inc (NASDAQ:HUMA) trade information
After registering a 1.34% upside in the latest session, Humacyte Inc (HUMA) has traded red over the past five days. The 5-day price performance for the stock is -3.53%, and -25.11% over 30 days. With these gigs, the year-to-date price performance is -32.38%.
The extremes give us $6 and $10 for target low and target high price respectively. As such, HUMA has been trading -193.26% off suggested target high and -75.95% from its likely low.
Humacyte Inc (HUMA) estimates and forecasts
Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 800.25k.
HUMA Dividends
Humacyte Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 4.73 million shares, or about 4.3693% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.7 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Humacyte Inc (HUMA) shares. Going by data provided on Dec 31, 2024, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 2.63 shares. This is just over 2.09% of the total shares, with a market valuation of $8.92 million. Data from the same date shows that the other fund manager holds a little less at 2.59, or 2.06% of the shares, all valued at about 8.79 million.
